Background--Although clinical trials have proved that statin can be used prophylactically against cardiovascular events, the direct effects of statin on plaque development are not well understood. We generated low-density lipoprotein receptor knockout (LDLR
A lthough the general consensus is that plaque rupture and erosion are the most common causes of acute coronary syndrome, the detailed process of plaque destabilization and definitive proof of unstable plaque remain elusive. 1 By applying intracoronary imaging modalities, such as intravascular ultrasound (IVUS) and optical coherence tomography, we can visualize developing plaques in vivo. However, IVUS and optical coherence tomography are usually performed only in patients who have had a heart attack requiring percutaneous coronary intervention. Even if we understand characteristics of the plaque on rupture or occlusion, it remains difficult to trace the plaque progression.
To understand the natural history of and the histopathologic mechanisms responsible for atherosclerotic plaque development, an animal model in which vulnerable plaques develop and data supporting a cause-and-effect relation are needed. 1 Animal models of atherosclerosis have been reported for several decades, but there are few that reproducibly exhibit the advanced plaques seen in humans, especially in the coronary arteries. Selective breeding of Watanabe heritable hyperlipidemic (WHHL) rabbits, however, has allowed development of advanced lesions with multiple necrotic zones in the main aortic and coronary branches. 2 Advanced lesions with intraplaque hemorrhage and rupture have also been observed in the innominate arteries of ApoE À/À mice. 3 However, ApoE À/À mice are resistant to coronary atherosclerosis, 2 and the coronary artery in the WHHL rabbit is too small for serial in vivo same-site intracoronary imaging of the process of plaque development. The small size also limits use of WHHL rabbit arteries in the development of human cardiovascular devices such as stents. Moreover, plaque in a main aortic branch such as the carotid artery is not similar to and only weakly correlated with plaque in the coronary artery. 4 For investigation into the development of coronary artery plaques, especially advanced plaques, an animal model with human-like coronary arteries is needed. The pig, by virtue of its similarity to humans with respect to size of the coronary artery, pathoanatomy, and physiology, is an ideal animal for the study of human coronary artery disease. 5 Porcine models of atherosclerosis have gained attention, and several pig/minipig models, such as the Rapacz familial hypercholesterolemic (FH) pig and the low-density lipoprotein receptor (LDLR) knockout Yucatan minipig, were developed recently. [6] [7] [8] [9] [10] [11] These models, however, are not ideal.
FH pigs show considerable variability in plasma cholesterol concentrations and atherosclerotic plaque development, 8 and LDLR knockout Yucatan minipigs need at least 6 months on a 40% fat, 1% cholesterol diet for development of coronary plaques. Furthermore, although the minipig is advantageous because of its size, it is in short supply and thus around 5 times more expensive than the domestic pig, making this model costprohibitive for many studies. In response to these obstacles, we knocked out LDLR from the domestic pig and generated a new LDLR knockout (LDLR À/À ) pig. Under a high-fat diet, advanced human-like plaques developed in the LDLR À/À pigs at a very young age, allowing for investigation after a relatively short developmental period. Several compelling clinical trials have supported statin treatment as prophylaxis against cardiovascular events.
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With development of our LDLR À/À pigs, we sought to take the next step in the research process to examine the direct effects of statin on the development of plaques, especially advanced plaques.
Methods Ethics Statement
The study was carried out in accordance with the National Institutes of Health "Guide for the Care 
Production of Cloned LDLR-Targeted Pigs
A conventional targeting vector for the porcine LDLR gene was constructed so that a major part of exon 4 was replaced by the neomycin resistance gene. The vector was introduced into fetal fibroblasts from Landrace 9 Large White crossbred pigs with use of the Gene Pulser II electroporation system (Bio-Rad Laboratories). The targeted cell clones were screened by polymerase chain reaction (PCR) and then used as donor cells for nuclear transfer. The nuclear transfer and subsequent embryo transfer were performed as previously described. 17 The cloned fetuses were collected at 39 or 72 days of gestation to confirm the targeting events by Southern blotting and so that large populations of cells could be obtained for further nuclear transfer. The cell populations that were confirmed to be targeted were used for the secondary nuclear transfer. F1 progeny were produced by artificial insemination or in vitro fertilization (IVF) with epididymal sperm collected from the clones. IVF was performed as described previously.
18 F2
and later progeny including homozygously LDLR-targeted (LDLR À/À ) pigs were produced by using conventional breeding methods involving heterozygously LDLR-targeted (LDLR
The extracted DNA was cut with SphI or NheI and EcoRV and then subjected to electrophoresis and transferred to nylon membranes. The membranes were hybridized with digoxigenin (DIG)-labeled 5 0 -or 3 0 -end probes, and the hybridization signals were detected with CSPD (Roche Applied Science, Indianapolis, IN).
Development of Advanced Coronary Artery Plaques
To accelerate the development of advanced coronary artery plaques, 3-month-old male LDLR À/À pigs (n=5) were fed a high-cholesterol, high-fat (HCHF) diet (1 kg/d) for 4 months (HCHF diet group). The HCHF diet was made from standard pig chow with 1.5% cholesterol and 15% fat (beef tallow). The fat was heated in a microwave oven before being mixed into the chow.
Statin Prophylaxis
Pitavastatin (40 mg/d) was administered along with the HCHF chow to 3-month-old male LDLR À/À pigs (n=6; statin prophylaxis group) for 4 months. Pitavastatin powder was obtained from Kowa Pharmaceutical Co Ltd. The powder was freshly mixed with a small amount of feed in the laboratory and was then added to the daily ration.
Laboratory Tests
Blood samples were obtained from both the HCHF diet group and statin prophylaxis group pigs before the treatment period and then once a month during the 4-month treatment period. 
iMAP-IVUS Analysis
At the end of the 4-month treatment period, all pigs, under general anesthesia, underwent coronary angiography and IVUS (Atlantis SR Pro 40-MHz Catheter; Boston Scientific Co) examinations for in vivo observation of coronary atherosclerotic plaques. IVUS images with radiofrequency signals were recorded continuously during an automatic pull-back maneuver at a constant speed of 0.5 mm/s. All of these iMAP-IVUS images were stored on DVD and were analyzed offline with the use of commercial software (echoPlaque 3.0; INDEC Systems). The external elastic membrane (EEM) area and lumen area were traced. The plaque area was calculated as the EEM area minus the lumen area, and plaque burden was calculated as the plaque area divided by the EEM area. In iMAP-IVUS analysis of plaque composition, various aspects of the radiofrequency signal are processed by autoregressive modeling and matched to a database of known radiofrequency signal profiles containing the characteristics of 4 basic tissue types. 20 The tissue components of the plaques were classified into the 4 basic types as fibrotic (green), lipidic (yellow), necrotic (red), and calcified (blue).
Histologic Analysis
The pigs were killed immediately after IVUS. The hearts with connected aorta roots were removed for fixation via coronary perfusion. The coronary arteries were flushed with normal saline for 30 minutes and then infused with 10% buffered formalin for 30 minutes at 150 cm H 2 O. The coronary arteries with surrounding tissues were removed from the heart. Sections of each coronary artery were taken perpendicular to the direction of blood flow at 1-cm intervals and embedded in paraffin ( Figure 1 ). These sections were stained with hematoxylin and eosin, elastic tissue fiber-Verhoeff-van Gieson, and Masson's trichrome. The lumen, internal elastic membrane, and EEM were traced. The EEM area was defined as the vessel area. The plaque area was calculated as the internal elastic membrane area minus the lumen area. When a plaque had a fibrous cap covering a necrotic core, the thickness of the fibrous cap was measured at its thinnest point. Thin-cap fibroatheroma (TCFA) was identified by a fibrous cap with a thickness of <65 lm. 21 All measurements were made with the use of ImageJ 1.46r (National Institutes of Health).
To evaluate the extent of atherosclerosis, we classified all lesions into 6 types according to the Stary criteria but with some modification. 22 In short, type I to III lesions were fibroatheroma; type VI: a type IV or type V lesion with fissure, hemorrhage, thrombus, or calcification). Lesions without a lipid core but with hemorrhage or calcification were considered type V lesions. In each coronary artery, the section with largest plaque area was selected for immunohistochemical detection of macrophages with the use of antimacrophage antibody MAC387 (Abcam). MAC387-labeled macrophages were identified under a microscope (BZ-X700; KEYENCE) and counted with the use of BZ-X Analyzer (BZ-analysis application, KEYENCE). 
Statistical Analysis

Results
Generation of LDLR À/À Pigs
We constructed a targeting vector for exon 4 of the porcine LDLR gene (Figure 2A ) and introduced it into porcine fetal fibroblasts. After selection with G418, 413 colonies were picked up to be screened by polymerase chain reaction. One (0.24%) of these colonies was shown to be targeted and used as a donor cell population. Six nuclear transfer and subsequent embryo transfer series yielded 9 fetuses from 2 pregnant female pigs ( Table 2 ). Seven of these were confirmed by Southern blotting to be correctly targeted. Fibroblasts from these targeted fetuses were used as donor cells for secondary nuclear transfer. Eleven nuclear transfers and subsequent embryo transfer series yielded 31 live-born piglets, but 29 of these died within 7 months, presumably because of epigenetic abnormalities caused by somatic cloning procedures (Table 2) . Because the 2 surviving pigs could not be subjected to the conventional sperm collection technique, owing to weakness of their hindlimbs, we retrieved epididymal sperm, which we used for artificial insemination or IVF. A total of 21 LDLR +/À F1 progenies were thus obtained.
From this F1 population, F2 and later progenies including LDLR À/À pigs were generated ( Figure 2B and 2C The serum cholesterol concentrations before the HCHF diet was started and at the end of the 4-month HCHF diet period are shown in Figure 4A . Serum cholesterol concentrations were significantly increased after 4 months in both LDLR Figure 4B , upper left and middle). However, when we dissected the coronary arteries from the hearts of these LDLR À/À pigs, massive, irregular atherosclerotic lesions were seen even from the vessel surface ( Figure 4B , lower images). When coronary arteries from LDLR À/À pigs were cut in cross -section, human-like advanced plaques with large necrotic cores and intraplaque hemorrhage were observed ( Figure 4B , upper right). In vivo IVUS and histological staining confirmed these human-like advanced plaques with necrotic cores and fibrous caps ( Figure 4C ), calcium deposits ( Figure 4D ), and intraplaque hemorrhage ( Figure 4E ).
4-month HCHF diet (
Effect of Statin Prophylaxis on Advanced Plaque Development
To test whether early statin treatment prevents the rapid development of advanced plaques found in LDLR À/À pigs fed comparable between pigs fed the standard chow diet and those fed the HCHF diet plus statin.
Results of the in vivo iMAP-IVUS analysis of the coronary arteries after 4 months of statin treatment are shown in Figure 6 . Although the lumen volumes were comparable between pigs fed the HCHF diet plus statin and those fed the HCHF diet alone, the plaque volume and vessel volume were significantly reduced in the statin prophylaxis group (Figure 6A and 6B) . In terms of plaque composition, the fibrotic, lipidic, and necrotic plaque volumes were also significantly decreased ( Figure 6A and 6C) .
Pathological examination, which was performed for all 1-cm sections obtained from each coronary artery (HCHF: n=132 sections, HCHF plus statin: n=157 sections), confirmed the reduced vessel and plaque areas seen on IVUS ( Figure 6D-6F) . Atherosclerotic lesions were confirmed in 80% of the coronary artery sections obtained from LDLR À/À pigs fed the HCHF diet. However, only 67% of sections from pigs fed the HCHF diet plus statin contained atherosclerotic lesions (P<0.01) ( Figure 7A ).
The extent of atherosclerosis also differed significantly between the LDLR À/À pigs fed the HCHF diet and the LDLR À/ À pigs fed the HCHF diet plus statin. As shown in Figure 7B , lesions in the statin prophylaxis group were predominantly of types I to III (HCHF versus HCHF plus statin, 45% versus 87%, respectively, P<0.01). Further, most advanced type VI plaques represented only 1% of plaques in this group, versus 10% in the HCHF diet group (P<0.01) ( Figure 7C ). We also investigated the proportions of sections showing TCFA, intraplaque hemorrhage and calcification, and the density of macrophage invasion, which are considered important factors in plaque instability. In LDLR À/À pigs fed the HCHF diet, 40% of the plaques with a fibrous cap were judged to be TCFAs. However, in LDLR À/À pigs fed the HCHF diet plus statin, only 8% of plaques with a fibrous cap were judged to be TCFAs (P<0.01) ( Figure 7D) . Similarly, the proportions of intraplaque hemorrhage differed significantly between these 2 groups of pigs (11% versus 1%, respectively; P<0.01) ( Figure 7E ), as did the proportions of calcification (22% versus 1%, respectively, P<0.01) ( Figure 7F ). The numbers of MAC387-labeled 
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Plaque area (10 4 macrophages were significantly reduced in the statin prophylaxis group (528AE120/mm 2 versus 150AE49/mm 2 , respectively; P<0.01) ( Figure 7G ).
Discussion
We produced hypercholesterolemia-induced human-like advanced coronary plaques in a porcine model of atherosclerosis by knocking out the endogenous LDLR gene. 28, 29 it is difficult to identify vulnerable plaque before a heart attack, even by angiographic examination. Our animal study verified the effects of early statin administration, before development of atherosclerosis, and provided histological evidence for early statin administration for primary prevention of advanced plaque development. Absence of the LDL receptor and differences between porcine apolipoprotein B and human apolipoprotein B may explain why the statin treatment did not decrease the LDL-C concentration in our LDLR À/À pigs. The protective role of statin in pig coronary atherosclerosis may come about via some pleiotropic mechanism rather than via its lipid-lowering effect. Inflammation plays a crucial role in atherogenesis, 13, 30 and the inflammatory biomarker CRP independently predicts vascular events and has been shown to be a stronger predictor of coronary heart disease than is LDL-C. [31] [32] [33] The serum CRP concentration was significantly increased in our LDLR À/À pigs after 3 months of being fed the HCHF diet.
However, statin treatment prevented this increase. These results are consistent with previously reported clinical data, 15, 34, 35 indicating that statin treatment reduces CRP in a manner that is independent of the LDL-C level. These results also suggest that the benefit of statin treatment is due in part to the control of serum CRP that is achieved with statin administration. Additionally, our identification of plaque macrophages leads us to believe that the statin treatment has a direct effect on inflammation at the cellular level. The statin treatment significantly reduced macrophage invasion, which is a key contributor to plaque vulnerability. 36, 37 Our findings should be considered in light of our study limitations. Our LDLR À/À pigs fed an HCHF diet more closely model familial hypercholesterolemia, which often manifests in early childhood as rapidly progressive cardiovascular disease, than they model the coronary artery disease seen in older patients, in whom most atherosclerotic plaques develop slowly over many years. In addition, we observed development of coronary atherosclerosis in the pigs fed the standard chow diet only until 6 months of age, that is, until they reached puberty. For a model that more closely resembles coronary artery disease in older patients, the pigs should be maintained taking the standard chow diet and observed for 1 year or longer. However, long-term observation of pigs is difficult because of their rapid increase in size and body weight. Thus, although LDLR À/À miniature pigs are several-fold more expensive than LDLR À/À domestic pigs, they are more suitable for long-term observation.
For the same reason, we did not observe plaque rupture in this experiment, even though we found several plaques with a papery fibrous cap covering a large necrotic core and thus prone to rupture. Future long-term serial in vivo observations involving IVUS and optical coherence tomography are needed for us to understand the full spectrum of atherosclerotic plaque development from appearance to rupture. We did not investigate the detailed pleiotropic mechanisms of the effects of statin on coronary artery atherosclerotic lesions. A small animal model, the ApoE À/À mouse, for example, is more suitable for investigating the signaling pathways in detail. Large animal models, such as our LDLR À/À pig model, are suitable for translational research, which bridges the gap between basic research and clinical application. In summary, results of our large animal experiment provide support for statin treatment before the occurrence of atherosclerosis. Early statin treatment appears to retard development of coronary artery atherosclerosis and ensure lesion stability. In addition, the LDLR À/À pigs we developed represent a large animal model of human-like advanced coronary plaque suitable for translational research.
